Abstract

Haleon plc will report its second‑quarter 2026 results before market open on July 30, 2026; this preview summarizes expected revenue and margin trends, key segment dynamics, and prevailing analyst views heading into the print.

Market Forecast

Based on management’s reiterated full‑year outlook and first‑quarter run‑rate, the market anticipates low‑single‑digit year‑over‑year revenue growth for the second quarter, broadly consistent with 3–5% organic growth for 2026. Consensus expectations point to gross margin remaining around the mid‑60% area and net profit margin in the mid‑teens, supported by steady price/mix and cost discipline; adjusted EPS forecasts are not available.

The main business is guided by continued brand investment and mix management, with oral care expected to remain resilient and selected recovery in cough/cold and pain categories as seasonal comparatives normalize into late quarter. Oral Health stands out as the most promising segment, with revenue of 3.46 billion British pounds last quarter in the segment disclosure and continued momentum from Sensodyne and Parodontax; while an exact year‑over‑year figure for the segment was not provided, trackers and company commentary indicate positive underlying demand.

Last Quarter Review

In the previous quarter, Haleon plc reported revenue of 2.75 billion British pounds, down 0.29% year over year, a gross profit margin of 65.03%, GAAP net profit attributable to shareholders of 430.00 million British pounds, a net profit margin of 15.51%, and adjusted EPS N/A.

A key business highlight was that organic sales grew by 2.2% but came in below market expectations due to softer over‑the‑counter cold and flu demand in the United States, partially offset by robust performance in oral care; management reaffirmed full‑year 2026 guidance for 3–5% organic revenue growth and high‑single‑digit adjusted operating profit growth on April 29, 2026. By category, Oral Health generated 3.46 billion British pounds, Pain Relief 2.56 billion British pounds, Respiratory Health 1.87 billion British pounds, Vitamins, Minerals and Supplements 1.69 billion British pounds, Digestive Health 987.00 million British pounds, and Therapeutic Skin Health and Other 460.00 million British pounds; YoY trends were mixed as respiratory categories faced normalization from prior flu seasons while toothpaste and gum‑health brands delivered sustained strength.

Current Quarter Outlook (with major analytical insights)

Main business: everyday health portfolio execution

For the second quarter, Haleon’s everyday health portfolio is positioned to deliver low‑single‑digit year‑over‑year growth anchored by pricing durability and targeted brand support. The key balancing act remains between normalization in seasonal cough/cold products in North America and broader resilience in non‑seasonal categories, including pain relief and daily oral care. Retail inventory levels in the U.S. are expected to be tighter than a year ago, limiting the risk of destocking pressure evident in certain staples peers earlier in the year and allowing underlying consumption to translate more cleanly to shipments late in the quarter.

Price elasticity continues to appear favorable in Haleon’s core categories, with trade promotion calibrated to protect share while preserving mix; that points to gross margin stability near the mid‑60% region seen in the prior quarter. Freight and selected commodities are benign versus last year, helping mitigate wage and media‑inflation headwinds, while the company’s ongoing productivity programs and increasing use of data and analytics in commercial execution support savings. Channel execution in North America has been under management focus since early 2026; commentary around distribution adjustments suggests a cleaner base into the second half, and investors will listen for evidence of improving order flow and category velocity, especially in pain relief aisles.

Foreign exchange remains a variable for reported results as a British pound denominator interacts with global sales; however, recent FX volatility has been moderate enough that portfolio‑level price/mix should dominate the quarter’s margin narrative. Beyond P&L lines, free cash conversion remains a watch item given inventory normalization through the first half and planned investments in technology and growth markets; a reaffirmation of cash conversion targets would be taken positively by the market. Altogether, this translates to the market expecting revenue up low‑single‑digit year over year, broadly steady gross margin, and a net margin profile near the mid‑teens.

Most promising business: Oral Health

Oral Health remains the crown jewel in Haleon’s portfolio with a structural runway supported by premiumization, science‑backed claims, and geographic expansion. The segment’s anchor brands Sensodyne and Parodontax continue to benefit from dentist endorsement and targeted innovation that ladders up to higher‑value sub‑ranges (e.g., sensitivity relief, gum health, enamel repair), which historically deliver favorable price/mix and defend share even in cautious consumer environments. Marketing effectiveness, including digital and professional education, is translating into sustained household penetration in developed markets and growing awareness in underpenetrated geographies.

Medium‑term catalysts for Oral Health were underscored by the June 8, 2026 announcement of a 175.00 million British pounds investment in India to establish a new oral health manufacturing facility and expand rural distribution to more than 3 million outlets by 2030. That capacity, targeted to supply both India and other Asian markets, addresses a critical supply‑chain lever for affordability tiers (e.g., smaller packs) and accelerates reach into fast‑growing and underserved communities, enhancing both volume growth and local responsiveness. Near term, the investment does not materially change Q2 revenue, but it strengthens the multiyear trajectory that analysts increasingly center in their Buy cases, particularly given India’s significant incremental consumer base and the segment’s strong brand equity.

Innovation cadence also remains healthy, with line extensions in sensitivity and gum‑health platforms, combined with packaging refresh and digital engagement, likely to support share gains in key markets. From a margin perspective, Oral Health’s premium skew and scale in media and procurement typically provide an uplift relative to the corporate average, reinforcing the case for stable to improving group gross margin when the segment over‑indexes in the sales mix. As Haleon leans into professional partnerships and education campaigns, the brand moat in sensitivity is expected to persist, offering the company a reliable ballast against variability in more seasonal categories.

Key stock price swing factors this quarter

The primary directional catalyst for Haleon shares around the print is whether Q2 organic growth sits comfortably within the 3–5% full‑year range, given the soft Q1 baseline and a progressively normalizing cough/cold category. If management points to firming trends in North America, particularly in pain relief and distribution quality, alongside steady oral care momentum, investors are likely to interpret that as de‑risking the second‑half trajectory. Conversely, any sign that category softness is broader than cough/cold seasonality, or that competitive intensity in U.S. self‑care is affecting shelf productivity, would raise questions about the cadence needed to deliver the high‑single‑digit adjusted operating profit growth guide.

Strategic updates carry additional weight this quarter. The company’s five‑year partnership with Microsoft announced on July 1, 2026, to expand AI and cloud deployment should help advance analytics in revenue‑growth management, demand forecasting, and media optimization; commentary quantifying early benefits to trade spend and working capital would be well received. Inorganically, media reports in late June 2026 indicated Haleon submitted a bid for U.S. supplements maker Thorne; any color on M&A priorities, return hurdles, and how a potential acquisition would complement the Vitamins, Minerals and Supplements (VMS) portfolio would influence sentiment on VMS acceleration without diluting margin discipline.

Shareholder technicals also matter. While not directly impacting operations, the market remains sensitive to supply overhang dynamics given historical selldown activity by legacy stakeholders; clarity on the medium‑term shareholder base and capital allocation—particularly the balance between organic investment, bolt‑on M&A, and deleveraging—could dampen perceived equity supply risk. Finally, investors will look for a clean reiteration of full‑year guidance and any qualitative steer on the trajectory into the back half, especially as the company faces easier cough/cold compares and executes its go‑to‑market adjustments in the U.S.

Analyst Opinions

Across recent notes published between March and July 2026, the balance of opinion is skewed bullish: roughly eight Buy ratings versus one Sell and one Hold, indicating a clear majority of positive views. On the bullish side, Barclays’ Warren Ackerman has maintained a Buy with a price target of 4.15 British pounds in multiple updates, framing the investment case around resilient fundamentals, Oral Health leadership, and pricing discipline that supports mid‑60% gross margins. Morgan Stanley’s Sarah Simon reiterated a Buy with a 440p target, highlighting robust oral care momentum and the prospect that North American trends improve as distribution and channel execution normalize through 2026.

Jefferies’ David Hayes also remains constructive with a Buy and a 400p target, arguing the company has structural growth potential and an attractive valuation setup despite near‑term demand softness in seasonal categories; he emphasizes the role of premium oral care and disciplined reinvestment in sustaining price/mix. Berenberg’s Bethan Davies has reiterated a Buy with a 512p target, citing the multi‑year runway in emerging markets and the accretive economics of trade‑up within sensitivity and gum‑health platforms. Kepler Capital has maintained a Buy stance with a 450p target, adding weight to the cluster of positive targets in the 400–512p range.

The common threads within the bullish camp are consistent. First, Oral Health is viewed as a durable growth engine with superior margin characteristics, capable of offsetting cyclical noise in seasonal OTC categories. Second, management’s reaffirmed 2026 guidance for 3–5% organic revenue growth and high‑single‑digit adjusted operating profit growth is seen as credible given Q1 underperformance was concentrated in cough/cold, while toothpaste and gum‑health outperformed. Third, the June 8, 2026 India investment and the July 2026 Microsoft partnership are framed as executional enablers—expanding capacity and affordability for high‑velocity oral care SKUs in Asia and sharpening revenue‑growth management and media productivity globally.

Bullish analysts also point to several potential upside catalysts around the Q2 print. If category normalization in cough/cold proves less of a drag than modeled and North American sell‑in trends improve, the quarter’s revenue growth could land in the middle of the 3–5% range rather than at the low end. Any incremental color on VMS strategy—including whether management pursues targeted M&A such as the mooted Thorne process—could further bolster the growth algorithm by layering a higher‑growth, science‑backed supplements platform into the mix. Finally, clear evidence of stable gross margins despite higher media investments would underscore the pricing and mix power embedded in the portfolio, supporting the case for sustained mid‑teens net margins.

In sum, the prevailing institutional view ahead of July 30, 2026 is that Haleon plc is set for a quarter of low‑single‑digit revenue growth with stable margins, underpinned by Oral Health strength and improving North American execution. The concentration of Buy ratings from Barclays, Morgan Stanley, Jefferies, Berenberg, and Kepler reflects confidence that Haleon’s brand equities and category mix can deliver on the 2026 framework and that recent strategic steps in technology and emerging‑market capacity add to visibility on multi‑year growth. While a minority of voices remain concerned about near‑term weakness in seasonal OTC categories, the majority expect stability and incremental progress in Q2, with the oral care engine continuing to anchor both top‑ and bottom‑line resilience.